Evidence map›Paper›PMID 39136754›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series.

Shoaib Ugradar, Emanuil Parunakian, Emil Malkhasyan, Pershanjit Raika, Joseph Tolentino, Andrea L Kossler, Kimberly Cockerham, Linus Amarikwa, David A Weinberg, Raymond S Douglas

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shoaib UgradarPrivate Practice, Beverly Hills, CA, USA.
Emanuil ParunakianPrivate Practice, Beverly Hills, CA, USA.
Emil MalkhasyanPrivate Practice, Beverly Hills, CA, USA.
Pershanjit RaikaPrivate Practice, Beverly Hills, CA, USA.
Joseph TolentinoPrivate Practice, Beverly Hills, CA, USA.
Andrea L KosslerByers Eye Institute, Stanford University School of Medicine, Palo Alto, USA.
Kimberly CockerhamPrivate Practice, San Diego, CA, USA.
Linus AmarikwaByers Eye Institute, Stanford University School of Medicine, Palo Alto, USA.
David A WeinbergConcord Eye Center, Concord, NH, USA.
Raymond S DouglasPrivate Practice, Beverly Hills, CA, USA. raymonddouglasmd@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTeprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of acute and chronic thyroid eye disease (TED) related to hyperthyroidism. Given the lower incidence of TED associated with hypothyroidism / euthyroidism, there is a paucity of data regarding the efficacy of teprotumumab in this group.

methodsIn this multicenter study, consecutive patients who had been diagnosed with TED, presenting with either hypothyroidism or euthyroidism as their baseline thyroid dysfunction and treated with teprotumumab were included. All patients had measurements of proptosis, clinical activity scores (CAS), diplopia scores and four-point strabismus scores before and after therapy.

resultsTwenty-six patients met the inclusion criteria. Mean age was 48 ± 14 years old and mean duration of TED prior to treatment was 31 ± 43 months. All patients received 8 infusions. Mean (SD) reduction in proptosis for study orbits was 2.7 mm (1.8) (p < 0.05) and 1.8 mm (2.0) for the fellow orbit (p < 0.05). In the study orbit, mean (SD) CAS was 2.3 (1.3) before therapy and 1.0 (1.0) following therapy (p < 0.05). At baseline, mean (SD) diplopia score was 1.2 (1.1) and 0.9 (1.1) following therapy (p < 0.05).

conclusionTeprotumumab reduces proptosis and inflammation in patients presenting with TED associated with hypothyroidism and euthyroidism. The results of this study highlight the potential for teprotumumab therapy in this subgroup and also provide a unique insight into the potential role of the IGF-1R in these patients.

Indexed as

Antibodies, Monoclonal, HumanizedGraves OphthalmopathyHypothyroidismAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedteprotumumabEuthyroidHypothyroidTeprotumumabThyroid eye diseaseThyroid eye disease treatment

Identifiers

PMID39136754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.